Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 1

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 1
---
umatic stress disorder (PTSD), and cognitive impairment.

At the effective time of the Merger (the “Effective Time”), each outstanding share of common stock of SKNY, $0.0001 par value per share (“SKNY Common Stock”), will be converted into the right to receive such number of shares of common stock of MIRA, $0.0001 par value per share (“MIRA Common Stock”) as is calculated in to the Exchange Ratio (the “Closing”). The Exchange Ratio is calculated using the relative company valuations of each of MIRA and SKNY where the MIRA share value is calculated on an as-issued basis and the SKNY share value is calculated on a fully diluted basis to include all issued SKNY options and warrants. After giving effect to the Closing, the SKNY holders will hold not more than 50% of the shares of the combined company.

Immediately after the Merger, the pre-Merger equity holders of MIRA are expected to hold approximately 50% of the outstanding shares of MIRA Common Stock and the pre-Merger equity holders of SKNY are expected to hold approximately 50% of the outstanding shares of MIRA Common Stock.

Shares of MIRA Common Stock are currently listed on The Nasdaq Global Market under the symbol “MIRA.” The post-Merger company will continue to trade on the Nasdaq under the symbol “MIRA”. On , 2025, the last trading day before the date of the attached proxy statement, the closing sale price of the MIRA Common Stock was $ per share.

MIRA is holding a virtual special meeting of its stockholders (the “MIRA virtual special meeting”) to obtain the stockholder approvals necessary to complete the Merger and related matters. MIRA has chosen to hold an exclusively virtual special meeting rather than an in-person meeting to allow for greater access to those who may want to attend. Any stockholder entitled to attend and vote at the MIRA virtual special meeting is entitled to appoint a proxy to attend and vote on such stockholder’s behalf. Such proxy need not be a holder of MIRA Common Stock. At the MIRA virtual special meeting, unless postponed or adjourned to a later date, MIRA will ask its holders of MIRA Common Stock to, among other things:

| 1. | approve                                                                                                                                  
 the issuance of shares of MIRA Common Stock or other securities of MIRA pursuant to the Merger, which will represent (or are convertible 
 into) more than 20% of